Clinical Trial Update: Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing adagrasib (MRTX849) to docetaxel in KRAS G12C-mutant non-small cell lung cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-22